]Stearic acid-labeled cerebroside sulfate (CS) was presented to cultured skin fibroblasts in the media. After endocytosis into control cells 86% was readily metabolized to galactosylceramide, ceramide, and stearic acid, which was reutilized in the synthesis of the major lipids found in cultured fibroblasts. Uptake and metabolism of the ['4C]CS into cells from typical and atypical patients and carriers of metachromatic leukodystrophy (MLD), Krabbe disease, and Farber disease were observed. Cells from patients with late infantile MLD could not metabolize the CS at all, while cells from an adult MLD patient and from a variant MLD patient could metabolize -40 and 15%, respectively, of the CS taken up. These results are in contrast to the in vitro results that demonstrated a severe deficiency of arylsulfatase A in the late infantile and adult patient and a partial deficiency (21-27% of controls) in the variant MLD patient. Patients with Krabbe disease could metabolize nearly 40% of the galactosylceramide produced in the lysosomes from the CS. This is in contrast to the near zero activity for galactosylceramidase measured in vitro. Carriers of Krabbe disease with galactosylceramidase activity near half normal in vitro and those with under 10% of normal activity were found to metabolize galactosylceramide in cells significantly slower than controls. This provides a method for differentiating affected patients from carriers with low enzyme activity in vitro. Cells from patients with Farber disease could catabolize only '-15% of the ceramide produced from
INTRODUCTION
Cerebroside sulfate (CS)' is a sphingolipid containing a sulfate moiety attached to carbon-3 of the galactosyl moiety that is attached in a beta linkage to ceramide (N-acylsphingosine). Its catabolism proceeds via specific lysosomal enzymes that sequentially catalyze the hydrolysis of the sulfate moiety, the galactose moiety, and the fatty acid moiety. Inborn errors of lipid metabolism at each step in the breakdown result in specific lipid storage in certain tissues and unique clinical features. Metachromatic leukodystrophy (MLD) is a disease caused by a deficiency of CS sulfatase (arylsulfatase A) (1), Krabbe disease or globoid cell leukodystrophy is caused by a deficiency of galactosylceramide ,B-galactosidase (2) and Farber disease or lipogranulomatosis is caused by a deficiency of acid ceramidase activity (3) . The deficiency of these enzymes has been demonstrated in leukocytes, cultured skin fibroblasts, and tissues, and this has permitted the reliable identification of most patients and carriers of these autosomal recessive diseases.
It recently has become apparent that measurements of lysosomal enzymes in vitro do not always give the correct genotype of the person who is being tested. The assays in vitro may require high concentration of bile salts or other additives to activate the enzyme in question. In recent years false positive or pseudode-ficient carriers (low enzyme activity in vitro in a healthy person) of MLD (4) (5) (6) (7) (8) (9) and Krabbe disease (10) have been reported. These families present a problem when prenatal diagnosis for the disease in question is requested. This problem has been resolved for MLD through studies using suitably labeled ([35S]sulfate or ['4C]stearic acid, labeled CS) in cultured skin fibroblasts and cultured amniotic cells (8, 9, 11) . In these experiments the labeled CS is presented to the cells in the media where it is taken up by endocytosis and subsequently metabolized in the lysosomes without the need for detergents or additives. This has resulted in the correct identification of fetuses with low in vitro activity in cultured amniotic cells and with either low turnover after uptake of [35S]CS (8) or near normal turnover after [14C]stearic acid-labeled CS (9) . This has not yet been reported for families who have a healthy family member with low levels of galactosylceramide B3-galactosidase. Shapiro et al. (12) described a patient with MLD who did not have the very low levels of CS sulfatase in vitro usually measured in patients with MLD. We must be able to clearly differentiate patients who have the disease in question (and perhaps delayed onset of symptoms) from healthy people who have enzyme levels near those of affected patients.
In this manuscript we describe the uptake and sub- [3H]borohydride method described previously (14) .
In vitro enzyme assays. The leukocyte and fibroblast pellets were homogenized in distilled water and used as the enzyme source without further purification. CS sulfatase activity was measured using NCS and ['4CJCS according to the method described previously (9) . Beta-galactosidase activities toward 4MU-IB-D-galactopyranoside, galactosylceramide, and lactosylceramide were measured as previously reported (15) . Total f,-hexosaminidase activity was measured using 4MU-3-N-acetylglucosaminide (15 Characterization of the radioactive metabolites. Radioactive regions from the thin-layer plate were eluted from the silica gel and cochromatographed with standard lipids as described previously (17) . Simple lipids were purified using thin-layer plates of silica gel H (0.25 mm thick) according to Skipski et al. (18) . Phospholipids were separated according to the procedure described and eluted from the gel. Further purification of phospholipids was achieved by development on precoated silica gel plates in chloroformmethanol-water (70-30-5, by vol). Each area identified on the autoradiogram was eluted with a mixture of chloroformmethanol-water. The ratio was made to 10-5-3 by vol and the lower phases were dried with nitrogen.
Methanolysis of glycerophospholipids was carried out by adding 1 ml of 0.1 N sodium methoxide according to the method of Svennerholm (19) . Sphingolipids and cholesterol ester were methanolyzed with 1 ml of 5% (by weight) HCI in methanol in a sealed tube for 16 h at 80°C. Fatty acid methyl esters were extracted with 1 ml of hexane three times.
The fatty acid methyl esters were analyzed by gas-liquid chromatography in a Hewlett-Packard 5710A apparatus (Hewlett-Packard Co., Palo Alto, CA) with a flame ionization detector and a radioactivity monitor. A 300-cm glass column of 2 mm i.d., packed with 5% OV-22 coated on 80-100 mesh Supelcoport (Supelco, Bellefonte, PA) was used. Fatty acid methyl ester standards were obtained from Sigma Chemical Co.
[3H]galactosylceramide uptake experiments. The media containing 5 nmol [3H]galactosylceramide (18,000 cpm/ nmol, radiopurity 93%)/ml was prepared as described for the [14C]CS uptake studies. After 2 and 4 d the media was removed and cells were harvested as described above. The lipids were extracted from the cells and -20,000 cpm were spotted on a thin-layer silica gel plate, and developed in chloroform-methanol-water (70-30-5, by vol). The dried plate was sprayed with a surface autoradiography enhancer (En3Hance spray, New England Nuclear) and exposed to xray film. The area corresponding to galactosylsphingosine (prepared from galactosylceramide by alkali hydrolysis [20] ) detected by exposure to iodine vapor was scraped and counted.
GMI ganglioside j3-galactosidase inhibition. To The media containing the compound to be tested was passed through a membrane filter (Millex-GS, 0.22 gm, Millipore (12, 21) , were found to have 27% of control activity using NCS and 21% of controls using CS as substrates.
Galactosylceramide and lactosylceramide #-galactosidase activities were severely deficient in cells from a patient with Krabbe disease. An obligate carrier was found to have 33-39% of control activities using these substrates. Two other healthy people were found to have very low activities using these two substrates in both leukocytes and cultured skin fibroblasts. One of these two was previously reported from this laboratory (10) . There was no history of Krabbe disease in that family. The other was the father of a child with typical Krabbe disease. Using galactosylceramide both had values <10% of controls. Their values were close to those measured in affected patients, and this demonstrated a potential problem in correctly identifying carriers in some families using only the in vitro assay.
CS sulfatase and 4MU-#-galactosidase activities in these pseudodeficient Krabbe carriers were within normal limits in both leukocytes (data not shown) and cultured skin fibroblasts.
In the cells from the patient and carriers of Farber disease the CS sulfatase, galactosylceramide f3-galactosidase, and 4MU-,8-galactosidase activities were within the normal limits. Their acid ceramidase activity has been reported to be <10% of controls in the patient and -50% of controls in the carriers (22 (n = 18).
1 had only 1% of normal 4MU-#-galactosidase activity, whereas the other enzymes checked were normal.
[14C]CS uptake experiments and characterization of metabolites. The 4 . In addition to galactosylceramide and ceramide, other radioactive spots corresponding to the major lipid components of cultured skin fibroblasts were found. They were identified as cholesterol ester, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, sphingomyelin, and GM3 ganglioside. More than 95% of the radioactivity was found in their fatty acid moieties after methanolysis. This was identified as stearic acid by gas chromatography indicating reutilization of the stearic acid after hydrolysis from ceramide.
The rate of hydrolysis of ["4C]CS taken up is shown on Fig. 2A, B . In Fig. 2A (Fig. 3A, B) . The control range was narrow as related both to time in culture and to amounts given to the cells (Fig. SA, B (Fig. 3A, B) . (Fig. 4A, B) Fig. 3A, B) . Although these experiments do not provide a satisfactory explanation for the significant metabolism of galactosylceramide in cell lines from patients with Krabbe disease, they do provide a basis for further experimentation.
DISCUSSION
The metabolism of [4GClstearic acid-labeled CS taken up by cultured skin fibroblasts from controls and from patients and carriers of certain lipid storage diseases is described. The substrate is of very high radiopurity (99.6%) and is relatively simple to prepare according to a published procedure (23) . Previous studies have demonstrated that CS could be incorporated into cultured skin fibroblasts, and that it could induce the formation of metachromatic inclusions in cells from MLD patients (24) . Ultrastructural studies revealed that these inclusions consisted of undigested CS in the lysosomes which lacked CS sulfatase activity (1). These observations support the conclusion that the catabolism of CS in intact cells takes place in the lysosome, and that the use of [C4G]stearic acid-labeled CS would be a useful substrate for the study of other lysosomal enzymes required for the complete catabolism of CS.
Uptake of ["GIGS into cells varied between cell lines with fast growing lines having the greatest incorporation. Therefore, a percentage distribution of metabolites was used to quantitate the enzymatic metabolism of [14CGCS. In cell lines from controls the [14C]CS is degraded to galactosylceramide, ceramide, and stearic acid, which then enters the fatty acid pool for the synthesis of the other major lipids found in cultured skin fibroblasts including phospholipids, gangliosides, and cholesterol ester (Fig. 1) . In cells from a patient with late infantile MLD practically no metabolism of the ["4C]CS was observed, which is in agreement with the in vitro findings (Table  I ). In cells from the patient with adult MLD the ["4C]CS could be metabolized at half the normal rate, which differs from the in vitro results, but provides an explanation for the later onset of the disease and the prolonged clinical course. When the cell line from the patient with the variant form of MLD (12, 21) (8, 11, 25) and our previous manuscript in which ["4CGCS was used under slightly different conditions (9) .
A near complete block in the degradation of
[14C]galactosylceramide was not observed in cell lines from patients with Krabbe disease (Fig. 1, 3A (Fig. 1, 3A, B) . This is in contrast to cell lines from carriers of MLD who metabolized CS-like controls and carriers of Farber disease who metabolized ceramidelike controls. This could indicate that galactosylceramide f,-galactosidase is the rate limiting enzyme in the degradation of galactosylceramide in cultured skin fibroblasts. Typical carriers of Krabbe disease, with 30-60% of control galactosylceramide ,B-galactosidase activity in vitro, and false positive carriers of Krabbe disease with 8-15% of control activities were similar in their abilities to degrade galactosylceramide in cultured cells. This finding is critical to the correct identification of patients and carriers, and for the ability to differentiate such people during prenatal diagnosis. Recently, Christomanou et al. (29) reported a significant psychometric difference between carriers and noncarriers of Krabbe disease. They presented evidence that carriers with <25% of control galactosylceramide /-galactosidase activity in vitro had significantly slower reaction times than normal. This finding may relate to our observations on the metabolism of galactosylceramide in intact cells.
Cultured skin fibroblasts from a patient with Farber disease could metabolize only -12% of the ceramide produced sequentially from CS, as compared to controls who could metabolize >90% by day 4 (Fig. 1, 4A, B) . These results differ significantly from those of Chen et al. (30) . In their studies, cultured cells were given a higher concentration of [3Hloleic acid-labeled ceramide. 
